Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors
Glorioso and colleagues describe the development of oHSVs that use VHH antibodies and affibody molecules to enhance retarget virus entry and spread in EGFR-expressing tumor cells. In vivo, systemic oHSV delivery resulted in tumor-specific replication and reduced tumor growth, whereas direct intratumoral delivery resulted in complete tumor regression.